Holmes is really smart for connecting with the right people early. Every account I've read of the woman is that she is incredibly smart and a relentlessly hard worker. Chances are she was able to impress a number of powerful people who backed her early, and she has been able to build a functional company (no small feat in itself) that is attempting to disrupt the medical testing industry.
A large part of successful disruption in heavily regulated industries is building a popular brand. Uber and Square are perfect examples of this: regulatory agencies are willing to bend over backwards to accommodate them in ways that they have never done. A large part of this is their popularity. I'm guessing that's why we're hearing so much about Theranos -- this is an industry that's largely hidden from the public eye, and she feels the best chance to disrupt the industry is if it's brought into the spotlight with Theranos at the forefront.
It could all be marketing fluff, but it's likely to be effective.
One thing that is good here is pricing transparency and legislation is moving now in states requiring that lab results have to be delivered from the lab directly to the patient if the patient requests it (New York recently did this). BUT that does not mean you can draw your own blood. You still need to have your blood drawn in the traditional way and sent out to a reference lab. So while direct to patient testing will certainly pan out, I do not see how this hot start up has any advantage over the many very large reference labs out there. With competition over HMO contracts for testing so fierce, testing margins have gone down a lot.
Currently Quest Diagnostics has a market cap of 8.4 billion, and is the largest reference lab in the USA. Valuation of 9.5 billion for a company with no specifics, no actual product and huge risks is absolutely ridiculous.
LabCorp made (income) $600 million last year. Quest made $1.5 billion.
They can afford teams of very capable developers. They can have the best software, the best presentation, slick mobile apps, speedy information systems.
They don't not because they can't afford it, but because they don't want to afford it. As is the case with many of these companies that get disrupted by tech startups, they see it as a cost center and minimize it.
Software rules the world. Any business that doesn't adapt to this will see strange little upstarts steal all of their thunder.
Regarding your point on Bayes Theorem, that's valid in some ways and invalid in some ways. Suppose someone gets a vitamin D test back at 8 ng/mL. There's not really a chance of a false positive. He's deficient and needs supplementation. Making the test cheaper, faster, and more accessible can really only improve the health of the population. It will likely also drive down the cost of healthcare overall, because vitamin D deficiency has all sorts of unpleasant effects.
Furthermore, the literature suggests that the vast majority of doctors do not understand Bayes Theorem. Source: http://yudkowsky.net/rational/bayes
Meanwhile, if I suspect that, for example, that my BMI veers into the obesity range when my TSH is high, it should be perfectly fine for me to try and get a $50 test to examine if there's a correlation. Better than spending that on a DVD of Keeping Up With the Kardashians, don't you think? Might even increase awareness about general health in the US.
There is maybe some marginal streamlining or process improvement possible, but you can already get blood drawn and a little while later have the results accessible on a mobile device. Sure, maybe the blood can be processed faster and those results should be available sooner and available to outside parties so you can use various apps and services; but that a policy and political problem, not really a technology challenge.
This company is just another one of those paper tiger companies... or maybe paper unicorn is a better metaphor ... who make something that is wholly unnecessary and the only thing they are good at is manufacturing buzz. Their technology solution seems to be an unnecessarily complex solution to a simple problem. We don't need to "know what your body is doing so you can live a healthier life", we just need to eat better and exercise far more. It's that focus on symptoms rather than causes that annoys the heck out of me. But I guess they have learned from the perpetual dependency model. You don't get to be a paper billionaire by telling people to stop being unhealthy, you become a paper billionaire by selling unnecessary stuff.
This is a very good point. My guess would be that we're seeing -- in this article, and in the Fortune profile linked on HN a few months ago -- the results of an incredibly well orchestrated and tightly controlled PR strategy. Say what you will about Elizabeth Holmes, but she is no dummy. She knows exactly what she is doing. The comparisons to Steve Jobs that seem to pop up in all of these articles are no accident. They feel intentionally cultivated, and perhaps to some degree, they're warranted. [1] Jobs also had a knack for image-making, be it in the tight control he exercised over the flow of information inside and outside his company, and in the image he ensured that the media portray.
Does the emperor wear no clothes here? I have no idea. I know next to nothing about the inner workings of the company, or about the medtech world (though I do find it fascinating). I do know that marketing matters a great deal, and traditional biotech and medtech companies don't seem to care too much about consumer image. They rely on time-tested sales channels and retail strategies. Theranos is different in the respect that it's running an Apple-esque marketing and PR playbook in an industry that traditionally does not.
"what these people are doing for lab testing, in terms of technology, sounds totally revolutionary IF YOU DON'T KNOW ANYTHING ABOUT CLINICAL LABS."
Yes, and I think Theranos/Holmes are well aware of that fact. If anything, they see it as an opportunity to seize a beachhead in consumer consciousness. The thinking process seems to be: most consumers know virtually nothing about how this all works, ergo, we can appear as gods before them. That is a speculative and perhaps cynical read, but at the same time, I admire their savvy. I admire it a great deal.
[1] Preemptive note: I am saying "to some" degree here. :) I'm not saying she is Steve Jobs, or that the comparison need extend any further, to any other dimensions, than in the specific area I'm talking about in this case. But I think you can make the case that someone who always appears in black turtlenecks, and has a way of invoking the name "Steve Jobs" in almost every major article about her, is intentionally aiming for the comparison. Which is exactly what Steve Jobs himself would have done, in a manner of speaking. (Cf., his intentional evocations of Edison, Ford, Picasso, etc.)
She's literally dressing like him for her self-promotional photos, in a way that was specifically mocked in HBO's "Silicon Valley" series recently.
I'd say it matters a great deal. Theranos has assembled a board with very strong ties to the government and, presumably, with an eye toward overcoming -- prophylactically or reactively -- any regulatory challenges that may arise. So, with the regulatory "defensive line" in place, so to speak, Theranos is free to focus on image, consumer marketing, and a steadily growing media blitz.
I would presume that its strategies right now include business development and channel alliances. As such, growing its mindshare and establishing itself as a breakthrough company -- and courting emotional comparisons to Apple -- will help with those goals. They will help by establishing awareness among partners, and indirectly, they'll help by fueling consumer demand. That's a time-tested channel marketing strategy. Companies as diverse as Apple, Nike, and Procter & Gamble are very good at running that playbook. Theranos is in a very differently industry, with a very different rulebook, and very different competitors. And it remains to be seen to what degree these efforts will matter. But they're not wasted efforts.
And I think people who work that much are more likely to make mistakes.
Theranos' technology is likely not going to blow my mind but I have to give them a lot of credit for incredible PR and (depending on how good the product actually ends up being) execution.
The FDA question is still really vital, of course.
The only thing interesting here is the amount of founding she has however the comparison with other start-ups and Steve Jobs is a very obvious marketing plot.
I will be interested to see how long it takes before a serious "the emperor has no clothes" article will come out in a mass media outlet, and someone who actually runs a lab or knows any of the rules of running labs is asked even one question. It is much less sexy of a story when told that way, so maybe never.